Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has secured an exclusive license from UniQuest to develop novel zinc ionophore technology aimed at fighting antimicrobial resistance to superbugs. This technology, which utilizes Alterity's PBT2, allows for the re-sensitization of bacteria to antibiotics, addressing a critical health issue. PBT2 has shown potential in reversing antibiotic resistance in preclinical studies and is patented until 2038. The partnership with UniQuest may significantly enhance Alterity's commercial prospects while maintaining focus on its primary program for ATH434.
Alterity Therapeutics (ATHE) announced the allowance of a new patent by the USPTO, covering over 150 novel compounds aimed at treating neurodegenerative diseases such as Parkinson's and Alzheimer's. This patent grants 20 years of exclusivity, bolstering the company's drug development portfolio. Alterity's lead candidate, ATH434, shows promise in clinical development, demonstrating favorable safety and efficacy in animal models. CEO Geoffrey Kempler emphasized the significance of this patent in pursuing innovative therapeutic options for serious brain diseases.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the start of patient enrollment for its bioMUSE Study focusing on Multiple System Atrophy (MSA) on Oct. 26, 2020. The study, conducted in collaboration with Vanderbilt University Medical Center, aims to track disease progression in early-stage MSA patients. The bioMUSE study data will inform the upcoming Phase 2 clinical trial of Alterity's lead compound, ATH434, which has completed Phase 1 trials. MSA is a debilitating neurodegenerative condition with no approved therapies, making this study crucial for advancing treatment options.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced new clinical data for its drug candidate ATH434, which will be presented at the 2020 International Congress of Parkinson's Disease and Movement Disorders and the American Neurological Association's Annual Meeting. New animal data confirms ATH434's effectiveness in reducing α-synuclein pathology and preserving neurons in a Multiple System Atrophy model. Additionally, new safety data indicates ATH434 has no significant cardiac liability, supporting its advancement to Phase 2 development after FDA discussions.
Alterity Therapeutics Limited (NASDAQ: ATHE) announced positive developments regarding its lead compound ATH434, receiving FDA guidance for its clinical development, including agreement on the Phase 2 study design. The company reported a cash balance of $9.2M, bolstered by an additional $1.5M from a recent share issuance. Furthermore, Alterity has resolved its previous compliance issue with NASDAQ regarding the minimum bid price requirement, confirming re-compliance.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a successful pre-IND meeting with the FDA regarding its lead compound, ATH434, for treating Multiple System Atrophy (MSA). Following a Phase 1 clinical trial, the FDA provided guidance on the Phase 2 study design, including safety monitoring and patient population. Importantly, there are no approved treatments for MSA, prompting collaboration with the FDA to establish appropriate efficacy endpoints. The company will also conduct a natural history study called bioMUSE to better track disease progression.